ELOX
Eloxx Pharmaceuticals, Inc.
$12.57
▲ +5.32%$12.57▲ +1142172.73%
over 1Y
L $0.00H $14.70
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.3%
1W+6.9%
1M—
3M—
YTD—
1Y—
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
High return on equity (50.3%); but revenue fell -100.0% YoY.
Revenue (FY2025) $0.00 · FY2025
Eloxx Pharmaceuticals, Inc. shows $0.00 in FY2025 revenue (-100.0% YoY), and 50.3% ROE.
Supporting the case: high return on equity (50.3%); conservative balance sheet (liabilities/equity -1.44x).
Is ELOX a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread~60d expiry
- Long put 12.5 @ ~11.98 est
- Short put 11.5 @ ~11.01 est
debit $97max +$3max −$97BE 11.53
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $6.36M | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$66.0M | -$34.4M | -$17.3M | -$2.47M | -$6.44M |
| Net income | -$66.7M | -$36.1M | -$17.1M | -$3.14M | -$6.00M |
| Diluted EPS | -$38.15 | -$16.65 | -$6.63 | -$0.84 | -$0.49 |
| Net margin | — | — | — | -49.4% | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$39.4M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-13.9%
FCF yield-14.8%
Quality & risk
ROIC (est.)—
Free cash flow-$6.39M
Total debt$1.00M
Net cash$3.79M
Altman Z-Score-85.08 distress
Piotroski F-Score2/8
Capital returns
Buyback yield—
Dividend yield (est.)0.0%
Shareholder yield0.0%
Shares Δ YoY+134.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2025-08-14). Worth a closer look.
- S-1/A Securities registration2026-06-04
- 8-K Officer / director change2026-06-01
- S-1/A Securities registration2026-06-01
- S-1 Securities registration2026-05-07
- 10-Q Quarterly report2026-05-05
- 8-K Shareholder vote2026-05-01
- 10-K Annual report2026-03-17
- NT 10-Q Late filing notice2025-08-14
- 8-K Officer / director change2025-08-12
Recent filings
all on EDGAR ↗SCHEDULE 13GFiling2026-06-17open ↗SCHEDULE 13GFiling2026-06-17open ↗4Period ending 2026-06-102026-06-17open ↗3Period ending 2026-06-052026-06-17open ↗SCHEDULE 13GFiling2026-06-16open ↗SCHEDULE 13GFiling2026-06-16open ↗SCHEDULE 13GFiling2026-06-15open ↗4Period ending 2026-06-082026-06-10open ↗4Period ending 2026-06-082026-06-10open ↗4Period ending 2026-06-082026-06-10open ↗4Period ending 2026-06-102026-06-10open ↗4Period ending 2026-06-082026-06-10open ↗
Frequently asked
- Is Eloxx Pharmaceuticals, Inc. (ELOX) a buy?
- ELOX currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. High return on equity (50.3%); but revenue fell -100.0% YoY.
- What is Eloxx Pharmaceuticals, Inc.'s quality score?
- ELOX scores 37.04255886611293/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001035354, latest 10-Q filed 2026-05-05) · EODHD · as of 6/23/2026, 12:45:37 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 22, 2026, 8:45 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.